Imugene Ltd has partnered with JW Therapeutics to develop a combination therapy for advanced solid tumors. The collaboration will evaluate Imugene’s oncolytic virus CF33-CD19 with JW’s Carteyva CAR-T cell therapy in preclinical and Phase 1 trials in China. This innovative strategy aims to enhance CAR-T therapy’s effectiveness in treating solid tumors by inducing CD19 expression on tumor cells.

Read more at Nasdaq: Imugene And JW Therapeutics Collaborate On Solid Tumor Therapy